Novartis sells joint venture stake to GSK for $13 billion

Novartis sells joint venture stake to GSK for $13 billion
x
Highlights

Swiss pharmaceutical firm Novartis says it is selling its stake in a consumer health care joint venture with GlaxoSmithKline to the British company for $13 billion.The joint venture was formed in 2015 and Novartis holds a 36.5-percent stake. 

GENEVA: Swiss pharmaceutical firm Novartis says it is selling its stake in a consumer health care joint venture with GlaxoSmithKline to the British company for $13 billion.The joint venture was formed in 2015 and Novartis holds a 36.5-percent stake.

Novartis CEO Vas Narasimhan said in a statement Wednesday that it "is progressing well," but "the time is right for Novartis to divest a non-core asset at an attractive price."

Novartis said the sale will be a cash transaction, and is subject to the approval of GSK shareholders. The four Novartis-appointed directors on the joint venture's board will step down when the sale is completed.

Show Full Article
Print Article
Interested in blogging for thehansindia.com? We will be happy to have you on board as a blogger.
Next Story
More Stories